Visteon (NASDAQ:VC – Get Free Report) and Aspire Biopharma (NASDAQ:ASBP – Get Free Report) are both consumer discretionary companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.
Institutional & Insider Ownership
99.7% of Visteon shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 2.0% of Visteon shares are owned by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Visteon and Aspire Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Visteon | 0 | 5 | 8 | 0 | 2.62 |
| Aspire Biopharma | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Visteon and Aspire Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Visteon | 5.58% | 14.61% | 7.07% |
| Aspire Biopharma | -11,362.21% | N/A | -177.59% |
Earnings and Valuation
This table compares Visteon and Aspire Biopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Visteon | $3.77 billion | 0.63 | $201.00 million | $7.65 | 11.60 |
| Aspire Biopharma | $10,000.00 | 1,229.20 | -$24.48 million | ($69.62) | -0.13 |
Visteon has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Visteon, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Visteon has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Aspire Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.
Summary
Visteon beats Aspire Biopharma on 12 of the 14 factors compared between the two stocks.
About Visteon
Visteon Corporation, an automotive technology company, designs, manufactures, and sells automotive electronics and connected car solutions for vehicle manufacturers worldwide. The company provides instrument clusters, including analog gauge clusters for 2-D and 3-D display-based devices; information displays that integrate a range of user interface technologies and graphics management capabilities, such as active privacy, TrueColor enhancement, local dimming, cameras, optics, haptic feedback, and light effects; and infotainment and connected car solutions, including scalable Android infotainment for seamless connectivity, as well as onboard artificial intelligence-based voice assistants with natural language understanding. It offers wired and wireless battery management systems; power electronics units; and telematics control units to enable secure connected car services, software updates, and data. In addition, the company provides SmartCore, an automotive-grade, integrated domain controller; SmartCore Runtime, a middleware enabling communication between domains and apps to be shown on any display; SmartCore Studio, a PC-based configuration tool to generate hypervisor configurations; and body domain modules, which integrate various functions, such as central gateway, body controls, comfort, and vehicle access solutions, into one device. Visteon Corporation was incorporated in 2000 and is headquartered in Van Buren, Michigan.
About Aspire Biopharma
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
Receive News & Ratings for Visteon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Visteon and related companies with MarketBeat.com's FREE daily email newsletter.
